Rubicon Research IPO Will Open On Oct 09, 2025 and Close On Oct 13, 2025.The ₹1,377.50 Cr. IPO Is A Book Build Issue, Consisting Entirely of Fresh issue and offer for Sale. Rubicon Research IPO Price Band Is Set At ₹461 to ₹485 per share.
The Allotment will Be Finalized On Oct 14, 2025 and Listing date is Expected on The NSE BSE By Oct 16, 2025. Investor Quota like 50% QIB, 35% Retail, and 15% HNI Category.
Financial Year 2025 Company Posted a Total income 1,296.22 Cr. and A Net Profit of ₹134.36 Cr. Showing Strong Growth From The Previous Year. Based On Financial, The IPO Looks Promising For Long-term Investors.
Rubicon Research IPO Dates & Price Band Details
| Open Date | Oct 09, 2025 |
|---|---|
| Close Date | Oct 13, 2025 |
| Price Band | ₹461 to ₹485 per share |
| Face Value | ₹1 per equity share |
| Lot Size | 30 Share |
| Type of Issue | Fresh issue & OFS |
| Total Issue Size | 2,84,02,040 shares (aggregating up to ₹1,377.50 Cr) |
| Fresh Issue | 1,03,09,278 shares (aggregating up to ₹500.00 Cr) |
| Offer for Sale | 1,80,92,762 shares of ₹1 (aggregating up to ₹877.50 Cr) |
| Employee Discount | ₹48 per Equity Share |
| Issue Type | Bookbuilding IPO |
| Listing Exchange | BSE & NSE |
| Retail Investor Quota | 35.00% |
| QIB Quota | 50.00% |
| NII (HNI) Quota | 15.00% |
| DRHP (Draft Prospectus) | Click Here |
| RHP (Final Prospectus) | Click Here |
About Rubicon Research India Limited
Our Company was originally incorporated on May 6, 1999 as “Rubicon Research Limited” We are a pharmaceutical formulations company, driven by innovation through focused research and development Company.
As on 31, March 2024, we had a Portfolio of 69 active ANDA & New Drug Application Products approved by the US FDA including 55 Commercialized products.
our Company’s portfolio includes 66 Commercialized Products as of March 31, 2025.
we have 17 new products awaiting US FDA ANDA approval and 63 product candidates in various stages of development.
one major chronic disease, such as heart disease, cancer, diabetes, obesity, and hypertension.
We believe our multi-disciplinary, data-driven, and return on investment (“ROI”) centric product selection framework is geared towards identifying sustainable opportunities for new product development. We identify and pursue such opportunities in a manner that provides us a competitive advantage by leveraging our development, manufacturing, and commercialization capabilities to create and grow our share of the market.
Our Competitive Strengths
We are the fastest growing Indian pharmaceutical company amongst our peers and the only Indian company focused completely on the US market.
Our data-driven product selection framework has allowed us to build a product portfolio with a combination of new and specialty products allowing us to withstand pricing pressures.
Our R&D capabilities and continuing investment allow us to pursue complex products that offer strong revenue opportunities.
Robust sales and distribution capabilities in the US.
Strong track record of compliance combined with expertise in cost effective manufacturing.
Experienced and entrepreneurial management team with a proven track record and marquee private equity investor.
Rubicon Research IPO Market Lot Size
The Minimum Lot Size For The Rubicon Research IPO is 30 Shares, Requiring An Application Amount of ₹14,550 For Retail Investors. Investors Must Apply in Multiples of The Lot Size.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 30 | ₹14,550 |
| Retail Maximum | 13 | 390 | ₹1,89,150 |
| S-HNI Minimum | 14 | 420 | ₹2,03,700 |
| S-HNI Maxmum | 68 | 2,040 | ₹9,89,400 |
| B-HNI Minimum | 69 | 2,070 | ₹10,03,950 |
Objects of Issue
Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by our Company.
Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes.
Rubicon Research IPO Allotment & Listing Dates
Rubicon Research IPO Will Open on Oct 09, and Close on Oct 13, 2025. The allotment is Expected on Oct 14, With the Listing Scheduled on NSE BSE For Oct 16, 2025 (More information below table).
| Anchor Investor Bidding | - |
|---|---|
| IPO Open | Thu, Oct 9, 2025 |
| IPO Close | Mon, Oct 13, 2025 |
| Allotment Finalisation | Tue,Oct 14, 2025 |
| Refunds / Unblocking | Wed, Oct 15, 2025 |
| Shares Credited to Demat | Wed, Oct 15, 2025 |
| Listing Date | Thu, Oct 16, 2025 |
Rubicon Research IPO Financial Report (FY 2025)
Rubicon Research Reported a Total Income of ₹1,296.22 Cr. in FY 2025, Slightly up From ₹872.39 Cr. in FY 2024. The Company Net Profit Also Rose to ₹134.36 Cr. From ₹91.01 Cr. in the Previous Year Showing Consistent Financial Growth Ahead of its IPO. (More information below table).
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,647.60 | 1,451.43 | 1,109.49 | 749.70 |
| Total Income | 356.95 | 1,296.22 | 872.39 | 419.00 |
| Profit After Tax | 43.30 | 134.36 | 91.01 | -16.89 |
| EBITDA | 79.74 | 267.89 | 173.09 | 43.97 |
| NET Worth | 593.67 | 540.98 | 385.00 | 286.38 |
| Reserves and Surplus | 397.50 | 525.57 | 369.79 | 281.31 |
| Total Borrowing | 495.78 | 393.17 | 396.41 | 317.91 |
| Amount in ₹ Crore |
Rubicon Research IPO Valuation Report – FY 2025 (KPI)
Check Detailed Rubicon Research IPO Valuation Metrics for FY 2025, including EPS, P/E Ratio, RoNW, NAV, ROCE, and other key financial indicators. These Ratios help Investors Assess the Company financial Health & Valuation Before applying for The IPO. (More information below table).
| KPI | Value |
|---|---|
| Return on Equity (ROE) | 29.02% |
| Return on Capital Employed (ROCE) | 26.45% |
| EBITDA Margin | 20.67% |
| PAT Margin | 10.37% |
| Debt-to-Equity Ratio | 0.73 |
| Earnings Per Share (EPS) | 8.82 |
| Price to Earnings Ratio (P/E) | 54.99 |
| Return on Net Worth (RoNW) | 29.02% |
| Net Asset Value (NAV) | 35.53 |
Our Company Promoters
General Atlantic Singapore RR Pte. Ltd.
Pratibha Pilgaonkar,
Sudhir Dhirendra Pilgaonkar,
Parag Suganchand Sancheti,
Surabhi Parag Sancheti,
Sumant Sudhir Pilgaonkar,
Rubicon Research Comparison With Industry Peers
| Name of Company | Face Value (₹) | CMP Sep 30, 2025 (₹) | EPS (₹) Basic | P/E | RONW (%) | NAV (₹ per share) | Revenue 2025 (in ₹ million) |
|---|---|---|---|---|---|---|---|
| Rubicon Research Limited | 1 | N.A. | 8.82 | 54.99 | 29.02 | 35.53 | 12,842.72 |
| Sun Pharmaceutical Industries Limited | 1 | 1,594.95 | 45.60 | 34.98 | 16.16 | 300.99 | 525,784.40 |
| Aurobindo Pharma Limited | 1 | 1,083.85 | 59.81 | 18.12 | 11.15 | 560.22 | 317,237.30 |
| Zydus Lifesciences Limited | 1 | 981.70 | 44.97 | 21.81 | 21.31 | 238.05 | 232,415.00 |
| Strides Pharma Science Limited | 10 | 824.75 | 44.05 | 18.72 | 17.51 | 277.34 | 45,653.35 |
| Dr. Reddy’s Laboratories Limited | 1 | 1,223.70 | 67.89 | 18.03 | 18.53 | 402.78 | 326,439.00 |
| Alembic Pharmaceuticals Limited | 2 | 900.20 | 29.68 | 30.33 | 11.83 | 264.09 | 66,720.80 |
| Lupin Limited | 2 | 1,910.15 | 71.95 | 26.64 | 21.00 | 377.18 | 227,079.00 |
Also Read: Rubicon Research IPO GMP Today, Grey Market Premium Live
Also Read: Mittal Sections IPO: Listing Price, GMP, Date, Review, Details
Also Read: Canara Robeco IPO: Listing Price, GMP, Date, Review & Details
Rubicon Research Company Contact Details
Corporate Office: MedOne House,
B-75, Road No. 33, Wagle Estate,
Thane West- 400 604, Maharashtra, India
Telephone: 022 61414000,
Email: investors@rubicon.co.in
Website: www.rubicon.co.in
Rubicon Research Lead Manager
Axis Capital Limited
1 st Floor, Axis House,
Pandurang Budhkar Marg, Worli,
Mumbai – 400 025, Maharashtra, India
Telephone: +91 22 4325 2183
E-mail: rubicon.ipo@axiscap.in
Website: www.axiscapital.co.in
IIFL Capital Services Limited
24th Floor, One Lodha Place,
Senapati Bapat Marg Lower Parel (West)
Mumbai 400 013,Maharashtra, India
Telephone: + 91 22 4646 4728
E-mail: rubicon.ipo@iiflcap.com
Website: www.iiflcap.com
JM Financial Limited
7th Floor, Cnergy,
Appasaheb Marathe Marg, Prabhadevi,
Mumbai – 400 025, Maharashtra, India
Telephone: +91 22 6630 3030
E-mail: rrl.ipo@jmfl.com
Website: www.jmfl.com
SBI Capital Markets Limited
1501, 15th Floor, A & B Wing
Parinee Crescenzo, BKC, Bandra (East),
Mumbai 400 051, Maharashtra, India
Telephone: +91 22 4006 9807
E-mail: rubicon.ipo@sbicaps.com
Website: www.sbicaps.com
Rubicon Research IPO Registrar
MUFG Intime India Private Limited
C-101, Embassy 247 L.B.S. Marg,
Vikhroli (West), Mumbai 400
083, Maharashtra, India
Telephone: +91 81081 14949
E-mail: rubicon.ipo @ in.mpms.mufg.com
Website: www.in.mpms.mufg.com
Rubicon Research IPO FAQs
Question 1: What is the Rubicon Research IPO?
Answer 1: Rubicon Research IPO is a Mainboard IPO of 2,84,02,040 equity shares of the face value of ₹1 approximately up to ₹1,377.50 Cr. The issue is price at ₹461 to ₹485 per share.
The Rubicon Research IPO opens on Oct 09 2025 and closes on 13, Oct 2025.
MUFG Intime India Private Limited is the registrar for the IPO. The shares to be listed on NSE BSE.
Question 2: How to apply in Rubicon Research IPO through Groww?
Answer 2: Groww customers can apply online in Rubicon Research IPO using UPI as a payment gateway. Groww customers can apply in Rubicon Research IPO by login into Groww (back office) and submitting an IPO application form.
Steps to apply in Rubicon Research IPO through Groww –
Visit the Groww website and login to Groww.
Go to Main Page and click the Products & tools and click IPO tab.
New page Open and Show ‘ Rubicon Research IPO’ click the ‘Apply’ button.
Show IPO detail Shares lot Size and Bid Price & click here to Cutoff Price check Box and Continue.
Inter Your UPI id like . 95****299@kotak accept terms and condition click Box and Apply For IPO
groww share payment link Your UPI Mobile Number Pay Payment for IPO Bid to approve the e-mandate successfully submit application .
Question 3: When Rubicon Research IPO will open?
Answer 3: The Rubicon Research IPO opens on Oct 09, 2025 and closes on Oct 13, 2025.
Question 4: What is the lot size of Rubicon Research IPO?
Answer 4: Rubicon Research IPO lot size and the minimum order quantity is 30 Shares.
Question 5: How to apply for Rubicon Research IPO?
Answer 5: You can apply in Rubicon Research IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don’t offer banking services. Read more detail about applying IPO online through Groww, Zerodha, Upstox, 5Paisa, Phonepe Share Market, HDFC Bank, and Angel one.
Question 6: When is Rubicon Research IPO allotment date?
Answer 6: The Basis of Allotment for Rubicon Research IPO will be on Tue, Oct 14, 2025, and the allotted shares will be credited to your demat account by, Wed, Oct 15, 2025, For Check the Rubicon Research IPO allotment status.
Question 7: When is Rubicon Research IPO listing date?
Answer 7: The Rubicon Research IPO listing date is Oct 16, 2025. The date of Rubicon Research IPO listing on Thu, Oct 16, 2025.
